HM15211, a novel GLP-1/GIP/Glucagon triple-receptor co-agonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multi-center, randomized, placebo-controlled trial
Year: 2020
Type: article
Source: Journal of Hepatology
Authors: Manal Abdelmalek, Jaeduk Choi, Youngmin Kim, Kyounghee Seo, Marcus Hompesch, Seungjae Baek
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4233941527
